Kornimate/medical-research-clean huggingface dataset:
pulsed dye laser and affirm laser in the treatment of abdominoplasty scars

Conditions: Abdominoplasty Scars

Summary: the purpose of this study is to examine the effect of using a pulsed dye laser (the vbeam), a non-ablative laser (the affirm) and a combination of both lasers to improve the appearance of your surgical scar. both the pulsed dye laser and affirm laser are approved by the us food and drug administration (fda) for the treatment of scars. surgical scars are a type of scar that can benefit from laser therapy. redness and the appearance of small blood vessels near the surface of the skin (telangiectasias) develop in such scars as part of the normal healing process and usually spontaneously remit, but often slowly and incompletely. in many cases, lasers can accelerate the clearing of this redness and also improve scar texture.

in summary, we will perform a total of three laser treatments. a personal interview, clinical examination, and a photograph will be taken at each visit. at the end of the three treatments, a final personal interview, clinical evaluation and photograph will be taken to document the effects of the laser treatments. at the end of the study, the patient will have the option to receive two additional laser treatments four weeks apart, also at no cost, to the entire scar.

Eligibility criteria:
inclusion criteria: * age 18 years and older * no significant medical illness * surgical procedure that involves closure of the transverse abdominal incision performed in the department of dermatology and plastic surgery at the cleveland clinic main campus. * subjects with the willingness and ability to understand and provide informed consent exclusion criteria: * under 18 years of age * pregnancy or lactation * subjects currently taking blood thinners or who have had chemotherapy or radiation within the last 6 months * subjects with liver/kidney disease, diabetes mellitus, hypertension, connective tissue disease or who are immunocompromised * subjects with a known susceptibility to keloid formation or hypertrophic scarring * subjects who are unable to understand the protocol or to give informed consent * subjects with mental illness * subjects with obvious non-healing wound

Keywords: post surgical
a study of nemtabrutinib vs chemoimmunotherapy for participants with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (cll/sll) without tp53 aberrations (mk-1026-008, bellwave-008)

Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma

Summary: researchers are looking for new ways to treat people with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll). cll and sll are types of blood cancer. researchers want to know if people who take nemtabrutinib compared to those who take the standard treatments in this study will live longer without their cancer growing, spreading or returning (progression free survival).


Eligibility criteria:
the main inclusion and exclusion criteria include but are not limited to the following: inclusion criteria: * confirmed diagnosis of chronic lymphocytic leukemia (cll)/ small lymphocytic lymphoma (sll) and active disease clearly documented to have a need to initiate therapy * has previously untreated cll/sll participants without tumor protein 53 (tp53) aberrations and documented 11q status and immunoglobulin heavy chain gene (ighv) mutational status * the ability to swallow and retain oral medication exclusion criteria: * active hepatitis b virus (hbv) or hepatitis c virus (hcv) infection * gastrointestinal dysfunction that may affect drug absorption (eg, gastric bypass surgery, gastrectomy) * known additional malignancy that is progressing or has required active treatment within the past 3 years, except basal cell carcinoma of skin, squamous cell carcinoma of skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone potential curative therapy * history of severe bleeding disorders * not adequately recovered from major surgery or has ongoing surgical complications
nac-003 p.l.u.s. program (progress through learning understanding & support)

Conditions: Early Memory Loss; Mild Cognitive Impairment; Alzheimer's Disease; Vascular Dementia

Summary: this study will be an observational study in which patients who have been prescribed cerefolinnac® are invited to participate in surveys regarding their experiences with cerefolinnac®. cerefolinnac® is a medical food indicated for the distinct nutritional requirements of individuals under treatment for early memory loss with particular emphasis for those individuals diagnosed with or at risk for neurovascular oxidative stress and/or hyperhomocysteinemia; mild to moderate cognitive impairment with or without vitamin b12 deficiency, vascular dementia or alzheimer's disease. the purpose of this study is to increase the understanding of the role of cerefolinnac® in managing proper neuronal function in the brain, provide patients with personalized education and support, and contribute to the overall understanding of the needs and concerns of patients being treated for early memory loss.

surveys used to conduct this study will be administered via telephone by infomedics, inc., a company with an established system for developing such patient-physician feedback programs. participating physicians will ask their patients to participate in the program after cerefolinnac® has been prescribed and provide them with a brochure containing an introduction to the program and instructions on how to enroll. patients self-enroll, take a brief survey before starting their cerefolinnac® prescription, and then two brief follow-up surveys at 6 weeks and 12 weeks. as patients complete surveys within the study, their physician will receive individualized feedback reports outlining their patient's treatment experience and progress. patients will also receive a copy of their own reports, to help encourage them to continue taking cerefolinnac® as directed. patients will also receive educational materials about managing their early memory loss.

Eligibility criteria:
inclusion criteria: * new cerefolinnac® start * only for patients who have been prescribed cerefolinnac® to help metabolic management of early memory loss. exclusion criteria: * if a participant indicates that he or she did not get a prescription for cerefolinnac®, he/she will not be able to complete the survey(s). * for follow-up surveys, if the participant indicates that he/she has not been taking cerefolinnac®, he/she will not be able to complete the survey (s).

Keywords: cerefolinnac early memory loss pre-alzheimer's disease cognitive function folic acid folate l-methylfolate vitamin b12 methylcobalamin n-acetylcysteine nac oxidative stress memory deficit antioxidant
economic evaluation of systemic treatments for moderate-to-severe psoriasis

Conditions: Psoriasis

Summary: this study is health economic analysis of medicinal treatment options for moderate-to-severe psoriasis vulgaris from the societal perspective. efficacy data and other clinical outcomes will be derived from an up-to-date meta-analysis of randomized clinical trials (rcts) for moderate-to-severe psoriasis. direct and indirect costs will be extracted from various different sources, including summary of product characteristics (spcs) and the german s3 guideline on psoriasis care, health care utilization data and official statistics. the study aims to investigate the comparative cost-effectiveness of biologic and conventional systemic treatments currently (as of june 1st, 2012) approved for moderate-to-severe plaque-type psoriasis in germany. effectiveness will be measured by means of the pooled (psoriasis area and severity index) pasi-75 response rates as reported in rcts direct cost as well as indirect cost will be considered.


Eligibility criteria:
inclusion criteria: -diagnosis of moderate-to-severe psoriasis exclusion criteria: -

Keywords: moderate-to-severe psoriasis cost utility analysis cost effectiveness analysis systemic treatment
adenomyosis: genomic mechanisms and biological response

Conditions: Adenomyosis; Abnormal Uterine Bleeding

Summary: examination of genomic and biologic responses to lng-ius in patients with adenomyosis.

examination of genomic and biologic responses to lng-ius in patients with adenomyosis.

Eligibility criteria:
inclusion criteria: * abnormal bleeding in the presence of adenomyosis as demonstrated by mri exclusion criteria: * other causes of abnormal bleeding such as fibroids, endometrial polyps, malignancy * presence of endometriosis
skin sparing mastectomy and immediate breast reconstruction with latissimus dorsi flap after neoadjuvant chemotherapy and radiotherapy (m-ric)

Conditions: Breast Carcinoma

Summary: the aim of the study is to evaluate the feasibility and morbidity of skin sparing mastectomy and immediate breast reconstruction with latissimus dorsi flap after neoadjuvant chemotherapy and radiotherapy in invasive breast carcinoma.


Eligibility criteria:
inclusion criteria: * women \< 75 year old * invasive breast carcinoma, indication for mastectomy * women health organization (who) score of 0 and 1, primary chemotherapy, external radiotherapy performed less than 8 week earlier... exclusion criteria: * women older than 75 * metastatic breast carcinoma * antecedents of previously treated homolateral breast carcinoma * documented cancer progression * smoker at the moment of the indication surgery * known diabetes, neoadjuvant hormonal treatment...

Keywords: invasive breast carcinoma
a study of the use of combination of anti-cholinergic and minor tranquilliser in the treatment of non-cardiac chest pain - a double blind placebo controlled study

Conditions: Chest Pain

Summary: non-cardiac chest pain is a common clinical problem encountered in our practice but at present, the results of treatments are unsatisfactory. the pathogenesis remains unknown but altered motility of the esophagus and psychological factors including anxiety have been implicated as important factors. reports of the single use of anticholinergic drugs and anxiolytics have yielded conflicting results, has been demonstrated to yield marginal or of no value. however the use of the combination therapy, especially with a double blind fashion have not been reported. on that basis, we propose to use a combination of anti-cholinergic and tranquilliser for the symptomatic treatment of non-cardiac chest pain. the aim of this study is to evaluate the efficacy of combination therapy of anti-cholinergic and anxiolytic drugs in the treatment of non-cardiac chest pain.


Eligibility criteria:
inclusion criteria: * ambulatory patients over the age of 18 * patients who are normal endoscopically * patients who do not have symptomatic reflux disease * patient who have normal coronary angiogram or patient with normal exercise radionuclide scan or patient with normal persantin radionuclide scan. exclusion criteria: * patients with history of significant cardiac, renal, pulmonary or hepatic diseases, * patients with history of dyspepsia or peptic ulcer diseases * patient with documented reflux diseases. * patient on drugs that affect gastrointestinal motility in the past 2 weeks * patients who are pregnant or lactating * patients who are suffering from costochrondritis * patients who are known to be sensitive to benzodiazepine or anti-cholinergic * patients with glaucoma and benign prostatic hypertrophy

Keywords: non-cardiac chest pain
comparison between propofol and inhalational anaesthetic agents on cardiovascular outcomes following cardiac surgery

Conditions: Coronary Heart Disease; Cardiovascular Diseases

Summary: the objective of this research proposal is to find out whether comparing the two different anaesthetic maintenance techniques (propofol vs volatile anaesthetics) in adult patients undergoing heart surgery is practical for the anaesthetist treating the patients and whether it is feasible for the research team to recruit patients and follow them up after the operation.

all patients undergoing heart bypass surgery are given anaesthetics during the operation. there are two types of anaesthetic commonly given to patients undergoing heart bypass surgery. propofol is an anaesthetic that is delivered into the patient's vein. other anaesthetics which are inhaled include isoflurane, sevoflurane and desflurane and these are called volatile anaesthetics. preliminary studies over the past ten years suggests that maintenance of general anaesthesia using only volatile anaesthetics has the potential to improve health outcomes after bypass surgery, when compared with propofol. volatile anaesthetics have been shown to protect the heart, the kidneys and the brain, however results of studies have been inconclusive. currently both volatile anaesthetics and propofol are used equally in clinical practice in the uk.

Eligibility criteria:
inclusion criteria: * patients (male and female) aged 18 years and above * written informed consent to participate * patients undergoing coronary artery bypass graft (cabg) surgery on cardiopulmonary bypass (cpb) with or without valve surgery * additive european system for cardiac operative risk evaluation (euroscore) of 5 or higher exclusion criteria: * pregnant or lactating women * allergy to propofol * previous diagnosis or suspected malignant hyperthermia * patients with a known sensitivity to any of the imps or other halogenated anaesthetics * concomitant therapy with glibenclamide or nicorandil (medications that may interfere with preconditioning) * inclusion in another clinical trial of an investigational medicinal product within the last 3 months.

Keywords: anaesthesia coronary artery bypass surgery cardioprotection
the role of antibiotic prophylaxis in lowering wound infection rates post-open repair of primary elective groin hernias in high-risk patients

Conditions: Antibiotic Prophylaxis; Wound Infection; Groin Hernia

Summary: this study aims to investigate the impact of antibiotic prophylaxis on reducing wound infection rates following open repair of primary elective groin hernias in high-risk patients.

this study will be a randomized controlled trial involving high-risk patients undergoing open repair of primary elective groin hernias. participants will be randomized into two groups: one receiving antibiotic prophylaxis and the other serving as the control group. the study will assess the incidence of wound infections postoperatively in both groups to determine the effectiveness of antibiotic prophylaxis in lowering infection rates.

Eligibility criteria:
inclusion criteria: * volunteer to participate in the study. * elderly patients aged over 60 years. * patients with diabetes. * or obese patients with a bmi greater than 35. * or immunocompromised patients. * or american society of anesthesiologists (asa) physical status classification 2 or more, with a history of more than 10 years. exclusion criteria: * non-cooperative patients for regular follow-up. * therapeutic indication for.

Keywords: groin hernia postoperative complications wound infection surgical site infection high-risk patients
does trans-cutaneous electrical nerve stimulation (tens) alleviate the pain experienced during bone marrow sampling?

Conditions: Pain

Summary: the approach of this study will be to answer the question does high-frequency stimulation trans-cutaneous electrical nerve stimulation (tens) alleviate the pain experienced during the bone marrow sampling procedure in addition to the standard analgesia given (ie. local anaesthetic with or without inhaled nitrous oxide). null hypothesis: tens does not alleviate the pain experienced during the bone marrow sampling procedure in addition to the standard analgesia given

patients in whom a bone marrow biopsy is planned will be randomised to one of two groups - a control-tens group where the tens machine will be set at the lowest sensory threshold and an intervention-tens group where the tens machine will be set at a recognised analgesic level (\>50 hertz (hz) and below the pain threshold for the patient) (bennett et al. 2011). the identity of the tens type will be concealed from both the patient and the doctor performing the biopsy. the primary outcome will be pain and this will be recorded by the patient immediately after the procedure using a validated numerical scale (0-10). all patients will receive standard pain relief (ie. local anaesthetic with or without inhaled nitrous oxide). the benefit of this study is to establish whether or not tens can benefit patients as an additional, safe, non-invasive and inexpensive method of pain relief during this frequently painful procedure.

Eligibility criteria:
inclusion criteria: * participant is willing and able to give informed consent for participation in the study. * male or female, aged 18 years or above. * participants are those medical patients seen in the haematology outpatients clinic for whom a bone-marrow trephine biopsy is deemed necessary either for diagnosis, staging or disease monitoring purposes. participants are either new patients or routine follow ups. * participant is able (in the investigators opinion) and willing to comply with all study requirements. * participant is willing to allow his or her general practitioner to be notified of participation in the study. exclusion criteria: * any known adverse reaction to high-frequency tens or electrode gel pads * any significant disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.

Keywords: pain bone marrow aspiration trephine biopsy
effects of micro-interventions on stress reactivity

Conditions: Psychological Stress; Physiological Stress

Summary: this study aims to investigate the effects of short, psychological interventions on bio-psychological stress responses after an acute stressor. the efficacy of two different approaches (expectation-bases vs. acceptance-based) will be compared to a control-group.


Eligibility criteria:
inclusion criteria: * fluent in german language exclusion criteria: * chronic disease * mental disease * the evening before the day of the experiment until end of the experiment (the next day): * caffeine, alcohol, intensive physical exercise, chewing gum * acute hay fever * current intake of psychotropic medication * current intake of orale contraceptives * visual impairments * heart conditions (self and close relatives)
atlantic lipid lowering treatment optimization program

Conditions: Familial Hypercholesterolemia; Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia; Apolipoprotein B 100, Familial Defective; High Density Lipoprotein Deficiency; Low-Density-Lipoid-Type Hyperlipoproteinemia

Summary: hypercholesterolemia is recognized as the major driver for cardiovascular morbidity and mortality. to help address this in our community, atlantic medical group (amg) formed a lipid workgroup chaired by robert d. fishberg, md, and jeffrey n. feldman, md. the overarching goal of the lipid workgroup is to enhance the treatment of lipid disorders in those patients with abnormal lipid levels by improving access to resources at the primary care practice level and specialty level. we aim to develop a model for primary and secondary prevention that integrates guidelines for treatment at the practice level. our primary objective is to identify high-risk patients by utilizing the electronic health record and partnering with patients' primary care providers to provide comprehensive medical management.

this study will screen patients with ldl-c \>160 mg/dl and with evidence of familial hypertension, reach out (using secure chat) to the attending practitioner of such patients and inform the practitioner of our comprehensive services to address fh. a study team member will inform the practitioner that one of the study team plans to reach out to their patient to inform the patient of the study. unless one of the study team receives notification by the practitioner that they want to opt out of this service for their patients, and do not want further interaction, the patient will be informed of the study and the consent process. the research question is: will an innovative comprehensive outreach approach, in conjunction with the primary care provider, reduce ldl-c levels in individuals with familial hypercholesteremia below individual baseline values, ideally at a level at or below 100 mg/dl.

Eligibility criteria:
inclusion criteria: * ldl-c ≥160 mg/dl * untreated ldl-c ≥190 with family history of cad * prior mi and currently without optimized lipid-lowering therapy * family history of cad in first degree relative * personal history of cad * untreated triglycerides \>500 * elevated lp(a) and/or high calcium scores * consenting individuals exclusion criteria: * individuals who are pregnant * individuals who are incarcerated * individuals with a terminal illness * individuals who do not consent

Keywords: treatment optimization; familial hypercholesterolemia; complex dyslipidemia
magnetocardiography endocrine registry

Conditions: Endocrine Disorder

Summary: endocrine disorders like type 2 diabetes mellitus (t2dm) represent complex cardiometabolic disease processes affecting approximately 462 million individuals worldwide and is associated with a two- to three-fold increase in cardiovascular mortality. individuals with t2dm are at an increased risk of developing cardiovascular disease. research has shown individuals with t2dm and no previous history of coronary artery disease are still at similar risk rates for cardiovascular events as patients with a prior myocardial infarction. the magenetocardiography endocrine registry (macendor) study is designed to collect cardioflux scans on a select group of volunteers who are high-risk patients with endocrine disorders. cardioflux is used as a noninvasive magnetocardiography (mcg) tool that analyzes and records the magnetic fields of the heart to screen volunteers for heart disease. there will be a 12-month duration of the study where we propose to collect screening data from approximately 250 volunteers who present to the genetesis facility for a 5-minute cardioflux scan. the volunteers will be contacted at intervals over a 1-year period for follow-up data and may choose whether or not they would like to provide follow-up data or participate in another scan.


Eligibility criteria:
inclusion criteria: 1. ≥ 18 years of age at the time of enrollment 2. patients deemed at risk for cardiovascular disease from endocrine disorders exclusion criteria: 1. \< 18 years of age 2. patients unable to fit into device 3. non-ambulatory patients 4. positive response(s) on cardioflux pre-screening form 5. patients with claustrophobia or unable to lie supine for five minutes 6. pregnant women 7. poor candidates for follow-up (e.g., no access to phone) 8. prisoners

Keywords: endocrine disorders mcg cardiovascular disease ischemia cardioflux